Inhibition_NN
of_IN
cyclooxygenase-2_NN
expression_NN
by_IN
4-trifluoromethyl_NN
derivatives_NNS
of_IN
salicylate_NN
,_,
triflusal_NN
,_,
and_CC
its_PRP$
deacetylated_VBN
metabolite_NN
,_,
2-hydroxy-4-trifluoromethylbenzoic_JJ
acid_NN
._.

The_DT
therapeutic_JJ
potential_NN
of_IN
drugs_NNS
that_WDT
block_VBP
the_DT
induction_NN
of_IN
cyclooxygenase-2_NN
has_VBZ
been_VBN
emphasized_VBN
._.

When_WRB
two_CD
4-trifluoromethyl_NN
salicylate_NN
derivatives_NNS
-LCB-_-LRB-
2-acetoxy-4-trifluoromethyl-benzoic_JJ
acid_NN
-LRB-_-LRB-
triflusal_NN
-RRB-_-RRB-
and_CC
its_PRP$
deacetylated_VBN
metabolite_NN
2-hydroxy-4-trifluoromethylbenzoic_JJ
acid_NN
-LRB-_-LRB-
HTB_NN
-RRB-_-RRB-
-RCB-_-RRB-
were_VBD
compared_VBN
with_IN
aspirin_NN
and_CC
sodium_NN
salicylate_NN
as_IN
cyclooxygenase-2_NN
-LRB-_-LRB-
COX-2_NN
-RRB-_-RRB-
inhibitors_NNS
,_,
we_PRP
observed_VBD
that_IN
in_IN
bacterial_JJ
lipopolysaccharide-activated_JJ
human_JJ
blood_NN
,_,
triflusal_NN
,_,
aspirin_NN
,_,
and_CC
HTB_NN
,_,
but_CC
not_RB
sodium_NN
salicylate_NN
,_,
inhibited_VBD
COX-2-mediated_JJ
prostaglandin_NN
E2_NN
-LRB-_-LRB-
PGE2_NN
-RRB-_-RRB-
production_NN
-LRB-_-LRB-
IC50_NN
=_JJ
0.16_CD
,_,
0.18_CD
,_,
0.39_CD
,_,
and_CC
&gt;_JJR
10_CD
mM_NN
,_,
respectively_RB
-RRB-_-RRB-
._.

However_RB
,_,
only_RB
triflusal_NN
and_CC
aspirin_NN
inhibited_VBD
purified_VBN
COX-2_NN
enzyme_NN
._.

To_TO
test_VB
this_DT
apparent_JJ
discrepancy_NN
,_,
we_PRP
realized_VBD
that_IN
HTB_NN
and_CC
triflusal_NN
-LRB-_-LRB-
but_CC
neither_CC
aspirin_NN
nor_CC
salicylate_NN
-RRB-_-RRB-
produced_VBD
a_DT
concentration-dependent_JJ
inhibition_NN
of_IN
COX-2_NN
protein_NN
expression_NN
in_IN
peripheral_JJ
human_JJ
mononuclear_JJ
cells_NNS
._.

This_DT
observation_NN
was_VBD
further_RB
confirmed_VBN
in_IN
a_DT
rat_NN
air_NN
pouch_NN
model_NN
in_FW
vivo_FW
,_,
in_IN
which_WDT
both_CC
aspirin_NN
and_CC
triflusal_NN
inhibited_VBD
PGE2_NN
production_NN
-LRB-_-LRB-
ID50_NN
=_JJ
18.9_CD
and_CC
11.4_CD
mg\/kg_NN
p.o._NN
,_,
respectively_RB
-RRB-_-RRB-
but_CC
only_RB
triflusal-treated_JJ
animals_NNS
showed_VBD
a_DT
decrease_NN
in_IN
COX-2_NN
expression_NN
._.

This_DT
different_JJ
behavior_NN
may_MD
be_VB
,_,
at_IN
least_JJS
in_IN
part_NN
,_,
due_JJ
to_TO
the_DT
ability_NN
of_IN
HTB_NN
and_CC
triflusal_NN
to_TO
block_VB
the_DT
activation_NN
of_IN
the_DT
transcription_NN
factor_NN
nuclear_JJ
factor-kappaB_NN
to_TO
a_DT
higher_JJR
extent_NN
than_IN
aspirin_NN
and_CC
sodium_NN
salicylate_NN
._.

Thus_RB
,_,
in_IN
addition_NN
to_TO
inhibiting_VBG
the_DT
COX-2_NN
activity_NN
at_IN
therapeutic_JJ
concentrations_NNS
,_,
triflusal_NN
is_VBZ
able_JJ
to_TO
block_VB
through_IN
its_PRP$
metabolite_NN
HTB_NN
the_DT
expression_NN
of_IN
new_JJ
enzyme_NN
,_,
and_CC
hence_RB
the_DT
resumption_NN
of_IN
PGE2_NN
synthesis_NN
._.

Triflusal_NN
and_CC
HTB_NN
may_MD
exert_VB
beneficial_JJ
effects_NNS
in_IN
processes_NNS
in_IN
which_WDT
de_FW
novo_FW
COX-2_NN
expression_NN
is_VBZ
involved_VBN
and_CC
,_,
in_IN
a_DT
broader_JJR
sense_NN
,_,
in_IN
pathological_JJ
situations_NNS
in_IN
which_WDT
genes_NNS
under_IN
nuclear_JJ
factor-kappaB_NN
control_NN
are_VBP
up-regulated_VBN
._.

